123 related articles for article (PubMed ID: 19369932)
1. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Schadendorf D
J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
3. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro.
Freudlsperger C; Moll I; Schumacher U; Thies A
Anticancer Drugs; 2006 Mar; 17(3):325-32. PubMed ID: 16520661
[TBL] [Abstract][Full Text] [Related]
5. Cloxiquine, a traditional antituberculosis agent, suppresses the growth and metastasis of melanoma cells through activation of PPARγ.
Zhang W; Shao W; Dong Z; Zhang S; Liu C; Chen S
Cell Death Dis; 2019 May; 10(6):404. PubMed ID: 31138783
[TBL] [Abstract][Full Text] [Related]
6. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
7. Anti-leukemic effects of PPARγ ligands.
Ryu S; Kim DS; Lee MW; Lee JW; Sung KW; Koo HH; Yoo KH
Cancer Lett; 2018 Apr; 418():10-19. PubMed ID: 29331412
[TBL] [Abstract][Full Text] [Related]
8. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Inamoto T; Shah JB; Kamat AM
Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510
[TBL] [Abstract][Full Text] [Related]
9. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.
Polikandriotis JA; Mazzella LJ; Rupnow HL; Hart CM
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1810-6. PubMed ID: 16020752
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones in dermatology.
Boyd AS
Int J Dermatol; 2007 Jun; 46(6):557-63. PubMed ID: 17550551
[TBL] [Abstract][Full Text] [Related]
12. Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone, in reperfusion injury: role of nuclear factor-kappaB, heat shock factor 1, and Akt.
Zingarelli B; Hake PW; Mangeshkar P; O'Connor M; Burroughs TJ; Piraino G; Denenberg A; Wong HR
Shock; 2007 Nov; 28(5):554-63. PubMed ID: 17589386
[TBL] [Abstract][Full Text] [Related]
13. Targeting glioblastoma stem cells (GSCs) with peroxisome proliferator-activated receptor gamma (PPARγ) ligands.
Im CN
IUBMB Life; 2016 Mar; 68(3):173-7. PubMed ID: 26818439
[TBL] [Abstract][Full Text] [Related]
14. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells.
Kaplan J; Cook JA; O'Connor M; Zingarelli B
Shock; 2007 Dec; 28(6):722-726. PubMed ID: 17621259
[TBL] [Abstract][Full Text] [Related]
16. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.
Kuntz S; Mazerbourg S; Boisbrun M; Cerella C; Diederich M; Grillier-Vuissoz I; Flament S
Biochem Pharmacol; 2014 Nov; 92(1):102-11. PubMed ID: 25083915
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
18. Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells.
Freudlsperger C; Dahl A; Hoffmann J; Reinert S; Schumacher U
Phytother Res; 2010 Sep; 24(9):1354-8. PubMed ID: 20812278
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma.
Shiau CW; Yang CC; Kulp SK; Chen KF; Chen CS; Huang JW; Chen CS
Cancer Res; 2005 Feb; 65(4):1561-9. PubMed ID: 15735046
[TBL] [Abstract][Full Text] [Related]
20. Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.
Yang C; Jo SH; Csernus B; Hyjek E; Liu Y; Chadburn A; Wang YL
Am J Pathol; 2007 Feb; 170(2):722-32. PubMed ID: 17255338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
